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1 
Sarcopenic obesity and its association with respiratory disease incidence and mortality 1 
Abstract 2 
Background - Sarcopenic obesity is defined as a combination of sarcopenia and obesity. Previous 3 
studies have shown a positive association between sarcopenia and respiratory disease, while other 4 
studies have identified that obese individuals have a lower risk for respiratory diseases. This study 5 
aimed to investigate the association of obesity, sarcopenia and sarcopenic obesity with respiratory 6 
disease incidence and mortality.  7 
Methods - Data from 170,083 participants from the prospective UK Biobank study were included. 8 
Sarcopenic obesity was defined as the combination of sarcopenia with one of the following obesity 9 
criteria: BMI ≥30 kg/m
2
, waist circumference (WC) ≥ 88 cm in women or ≥ 102 cm in men, or the two 10 
highest quintiles of body fat. Respiratory disease incidence and mortality were the outcomes. 11 
Results - The mean follow-up period was 7.0 years. 5,459 (3.2%) participants developed respiratory 12 
diseases and 780 (0.5%) died from respiratory diseases. Compared to individuals without obesity or 13 
sarcopenia, those who were obese (Hazard Ratio (HR): 1.13 [95 CI: 1.03; 1.23]), sarcopenic (HR: 1.23 14 
[95% CI: 1.10; 1.36]) or sarcopenic obese (based on BMI) (HR: 1.51 [95% CI: 1.30; 1.77]), had a higher 15 
risk of respiratory disease incidence. However, the risk of respiratory disease mortality was higher in 16 
sarcopenic individuals and lower in obese individuals. No associations were identified between 17 
sarcopenic obesity and respiratory mortality (HR: 1.12 [95% CI: 0.76; 1.63]). Similar patterns were 18 
found when obesity was defined using WC or body fat.  19 
Conclusion – Obesity, sarcopenia and sarcopenic obesity were associated with a higher risk of 20 
respiratory disease incidence. However, while obesity was associated with lower, and sarcopenia 21 
with higher respiratory mortality risk, no associations between sarcopenic obesity and respiratory 22 
mortality were identified.  23 
Keywords: Sarcopenia; Obesity; Respiratory disease; Respiratory mortality 24 
Word count: 2,805 25 
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Introduction  26 
Obesity is a chronic, progressive and recurring disease, and it remains one of the biggest public 27 
health challenges worldwide [1, 2]. Sarcopenia, on the other hand, is defined as an age-associated 28 
decline in muscle strength, mass and physical performance [3-5]. Both conditions can occur 29 
independently of each other; however, they share a common inflammatory pathway and are 30 
independently associated with more rapid functional decline and a higher risk of disease and 31 
mortality [6-8]. Although older people with sarcopenia are at higher risk of an unintentional weight 32 
loss [9], the prevalence of obesity among adults of all ages, including older adults, has increased 33 
since 1980. It is not surprising, therefore, that the prevalence of individuals with both sarcopenia 34 
and obesity has increased as well [10, 11]. 35 
Sarcopenic obesity is the term used to define the presence of both conditions (obesity and 36 
sarcopenia). Reduced lean mass with an excess percentage of body fat was one of the first 37 
definitions of sarcopenic obesity [12, 13]. Nevertheless, alternative operational definitions have 38 
been proposed based on different obesity markers: body mass index (BMI), waist circumference 39 
(WC) or visceral fat mass [12]. 40 
Previous studies have shown a positive association between sarcopenia and respiratory disease 41 
incidence and mortality [14, 15] and interestingly, other studies have shown that being overweight 42 
or obese is associated with a reduced risk of respiratory disease [16-18]. Although sarcopenic obesity 43 
has been associated with a higher risk of all-cause, cardiovascular disease and cancer mortality [19-44 
22], to our knowledge, no studies have been carried out investigating the associations between 45 
different sarcopenic obesity definitions and respiratory diseases. This is particularly important due to 46 
the differential associations of sarcopenia and obesity with respiratory disease. Therefore, this study 47 
aimed to investigate the association of obesity, sarcopenia and sarcopenic obesity with respiratory 48 







Between April 2007 and December 2010, UK Biobank recruited over 500,000 participants (5.5% 54 
response rate), aged 37-73 years from the general population [23]. Participants attended one of 22 55 
assessment centres across England, Wales and Scotland [24, 25] where they completed a touch-56 
screen questionnaire, had physical measurements taken, and provided biological samples, as 57 
described in detail elsewhere [24, 25]. 58 
The outcomes in the current study were respiratory disease incidence and mortality, and the 59 
exposure were adiposity markers, sarcopenia and sarcopenic obesity. Due to ethnic differences in 60 
the reference values for sarcopenia, inclusion in the study was restricted to participants of a white 61 
European background.   62 
Procedures 63 
Respiratory disease was defined as ICD10 codes J09-J98 and I26-I27 recorded on hospital admission 64 
or death records. Date and cause of death were obtained from death certificates held by the 65 
National Health Service (NHS) Information Centre (England and Wales) and the NHS Central Register 66 
Scotland (Scotland). Dates and causes of hospital admissions were identified via record linkage to 67 
Health Episode Statistics (HES) (England and Wales) and the Scottish Morbidity Records (SMR01) 68 
(Scotland). The detailed information regarding the linkage procedure can be found at 69 
http://www.ic.nhs.uk/services/medical-research-information-service. End of follow-up for each 70 
participant was recorded as the date of death, date of first hospital admission for respiratory 71 
disease, or the date of the end of follow-up for the assessment centre attended (31st January 2018 72 
for participants in England or Wales, and 30th May 2017 for participants in Scotland), whichever 73 
came first. The period at risk per participant began on the date of their assessment.  74 
Adiposity markers 75 
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Height was measured to the nearest centimetre (cm) using a Seca 202 height measure, and a Tanita 76 
BC-418 body composition analyser was used to measure weight to the nearest 0.1 kg. Both were 77 
used to estimate BMI and the WHO criteria were applied to categorise participants into underweight 78 
<18.5, normal weight 18.5-24.9, overweight 25.0-29.9 and obese ≥30.0 kg.m
-2 
[26]. WC was used to 79 
derive central or abdominal obesity, defined as ≥ 88 cm for women or ≥ 102 cm for men [26]. Body 80 
composition was measured using bioimpedance (BIA) by trained nurses. Obesity by body fat was 81 
defined as body fat ≥ 26.9% in men, and ≥ 38.6% in women. These cut-off points values represent 82 
the two highest sex-specific quintiles in the UK Biobank population [27]. Using these adiposity 83 
markers, we created 3 obesity variables: people with abdominal obesity but without sarcopenia, 84 
people with obesity based on BMI but without sarcopenia, and people with obesity by body fat but 85 
without sarcopenia (Supplementary Figure 1).   86 
Sarcopenia  87 
The 2010 European Working Group on Sarcopenia in Older People (EWGSOP) guidelines defined 88 
sarcopenia as the combination of low muscle mass plus and either low grip strength or slow gait 89 
speed [28]. Individuals with any of these classifications but without obesity were classified as 90 
sarcopenic (Supplementary Figure 1).  91 
Grip strength was measured using a Jamar J00105 hydraulic hand dynamometer. The means values 92 
of the right and left hand were expressed in absolute units (kg) and used in subsequent analyses. 93 
The cut-off points used to define low grip strength were <30 kg in men and <20 kg in women [28].  94 
Muscle mass index was derived from skeletal muscle mass (kg) divided by height (m) squared. To 95 
estimate the skeletal muscle mass, the Janssen equation was utilised [29] using the resistance value 96 
generated during the measurement of body composition measured using  BIA. The cut-off points 97 
used to define low muscle mass were <8.87 kg.m
-2
 in men and <6.42 kg.m
-2 
for women [28]. Finally, 98 
the self-reported walking pace was utilised as a proxy of gait speed. Participants categorised their 99 
5 
 
usual walking pace as slow, average or brisk and, to derive a proxy for the EWGSOP-2010 definition 100 
of usual walking pace, this was then dichotomised into slow or normal (average or brisk pace).  101 
Sarcopenic obesity 102 
There are different criteria and cut-off points used to define sarcopenic obesity [30]. In this study, 103 
we define sarcopenic obesity based on three different obesity markers (Supplementary Figure 1). a) 104 
sarcopenic obesity based on BMI (sarcopenia plus BMI ≥ 30.0 kg.m
-2 
[26]); b) sarcopenic obesity 105 
based on WC (sarcopenia plus WC ≥ 88 cm for women and ≥ 102 cm for men [26]); c) sarcopenic 106 
obesity based on body fat (sarcopenia plus body fat ≥ 26.9% in men and ≥ 38.6% in women [27]).  107 
Covariates 108 
Age was calculated from dates of birth and baseline assessment. Area-based socioeconomic status 109 
(deprivation) was derived from the postcode of residence, using the Townsend score [31] which 110 
generates a deprivation score based on four census variables; unemployment, non-car ownership, 111 
non-house ownership and household overcrowding. In this study, the Townsend score is presented 112 
by quintiles of deprivation (from the least deprived to the most deprived). Self-reported smoking 113 
status was categorised as never, former or current smoker. The mean of forced expiratory volume in 114 
one second (FEV1) was estimated in litres using a spirometer (Vitalograph Pneumotrac 6800). The 115 
participants were asked to record two to three blows (lasting for at least 6 seconds) within about 6 116 
minutes. The mean FEV1 of these records was used. Physical activity was based on self-reported 117 
data, collected using the International Physical Activity Questionnaire (IPAQ) short form [32] and 118 
total physical activity was computed as the sum of walking, moderate and vigorous activity, 119 
measured as metabolic equivalents (MET-hours/week). Total time spent in sedentary behaviours 120 
was derived from the sum of self-reported time spent driving, using a computer and watching 121 
television. Medical history (physician diagnosis of depression, stroke, angina, heart attack, 122 
hypertension, cancer, diabetes, hypertension, chronic obstructive pulmonary disease [COPD] or 123 
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other illness) was self-reported. Further details of these measurements can be found in the UK 124 
Biobank online protocol (http://www.ukbiobank.ac.uk).  125 
 126 
Statistical analyses 127 
Descriptive characteristics of each variable are presented as mean with standard deviation (SD) for 128 
quantitative variables or as a proportion for categorical variables.  129 
Associations between obesity variables, sarcopenia, sarcopenic obesity classifications and 130 
respiratory disease incidence and mortality were investigated using Cox-proportional hazard models 131 
(individuals without sarcopenia nor obesity were used as the reference group). The results are 132 
reported as hazard ratios (HR) and their 95% confidence intervals (95% CI). The proportional hazard 133 
assumption was checked by tests based on Schoenfeld residuals. All analyses were performed using 134 
a 2-year landmark analysis to exclude participants having respiratory disease events in the first two 135 
years of follow-up. Participants with medical diagnoses of respiratory disease at baseline were also 136 
excluded. In addition, to predict the number of respiratory deaths per number of cases of respiratory 137 
diseases for each obesity variable, sarcopenia and sarcopenic obesity definitions, the case-fatality 138 
rate was estimated.   139 
All analyses were adjusted for confounding factors, including socio-demographic covariates (age, 140 
sex, gross income and education attainment), prevalent diseases (hypertension, diabetes, 141 
depression, major illness, as well as CVD, and cancer) and lifestyle factors (smoking, sleep duration, 142 
physical activity, total discretionary sedentary time and dietary intake including alcohol, fruit and 143 
vegetable, oily fish, red meat and processed meat intake) at baseline.  144 
STATA 14 statistical software (StataCorp LP) was used to perform the analyses. P-values below 0.05 145 
were regarded as statistically significant. 146 
Ethical Approval  147 
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UK Biobank was approved by the North West Multi-Centre Research Ethics Committee, and all 148 
participants provided written informed consent to participate in the UK Biobank study. The study 149 
protocol is available online (http://www.ukbiobank.ac.uk/).  150 
Results 151 
Of the 502,628 participants recruited to UK Biobank, 170,083 (33.8%) had full data available on 152 
exposure, outcomes and covariates (Supplementary Figure 1). The mean follow-up period was 7.0 153 
years (interquartile range: 6.4–7.6) after the landmark period for respiratory disease mortality, and 154 
6.1 years (interquartile range: 5.4–6.7) after the landmark period for respiratory disease incidence. 155 
Over the follow-up period, 5,459 (3.2%) participants developed respiratory disease, and 780 (0.5%) 156 
participants died from respiratory diseases. The highest respiratory disease-specific case fatality rate 157 
was in those with sarcopenia (22.9%), followed by those with sarcopenic obesity based on body fat 158 
(20.6%), sarcopenic obesity by WC (19.0%), sarcopenic obesity by BMI (18.2%), people without 159 
sarcopenia nor obesity (12.4%) and finally, those with any form of obesity (abdominal obesity 160 
[10.4%] obesity based on body fat [10.2%], and obesity by BMI [9.6%]). 161 
The main characteristics of participants are presented in Table 1 and Supplementary Tables 1 and 2. 162 
Overall, and in comparison to people without obesity or sarcopenia, fewer women were obese while 163 
those with sarcopenia or sarcopenic obesity were older and were the most deprived (Table 1). In 164 
comparison to people with obesity, those with sarcopenic obesity had a lower body weight, BMI, WC 165 
and body fat. Those with sarcopenia and sarcopenic obesity had the lowest height, lowest levels of 166 
grip strength and physical activity whereas those with obesity or sarcopenic obesity had the highest 167 
levels of sedentary behaviour, TV viewing and the highest intake of processed and red meat. These 168 
two groups also had the highest prevalence of diabetes, CVD diseases and high blood pressure. 169 
Finally, FEV1 was lower in those with sarcopenia and even lower in those with sarcopenic obesity 170 
(Table 1). Similar characteristics were found in those with sarcopenic obesity defined by WC and 171 
body fat (Supplementary Tables 1 and 2, respectively).  172 
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As shown in Figure 1a, obesity (defined by BMI), sarcopenia and sarcopenic obesity were associated 173 
with a higher risk of respiratory disease incidence. Compared to the reference group (individuals 174 
without obesity or sarcopenia), those who were obese and those who had sarcopenia had a 13% and 175 
23% higher risk of respiratory disease incidence (HR 1.13 [95% CI: 1.03 to 1.23] and HR: 1.23 [95% CI: 176 
1.10 to 1.36], respectively). Furthermore, respiratory disease incidence risk was higher in individuals 177 
with sarcopenic obesity compared to individuals without sarcopenia nor obesity (HR: 1.51 [95% CI: 178 
1.30 to 1.77]). Similar findings were found when sarcopenic obesity was defined by WC o body fat 179 
(Supplementary Table 3).  180 
The associations of respiratory disease mortality with obesity, sarcopenia and sarcopenic obesity are 181 
presented in Figure 1b. In comparison to individuals without sarcopenia nor obesity, those with 182 
obesity by BMI had a lower risk of respiratory disease mortality (HR: 0.62 [95% CI: 0.48 to 0.79]) 183 
whilst those with sarcopenia had a higher risk (HR: 1.45 [95% CI: 1.12 to 1.88]), with no association 184 
found of sarcopenic obesity with respiratory mortality (HR: 1.12 [95% CI: 0.76 to 1.63]). When 185 
sarcopenic obesity by WC or body fat was the exposure, similar results were found (Supplementary 186 
Table 3).  187 
 188 
Discussion 189 
Sarcopenic obesity leads to a worse prognosis and increases the risk of all-cause mortality in people 190 
with both conditions [19-22]. To our knowledge, the current study is the first to investigate the 191 
associations of sarcopenia, obesity and sarcopenic obesity with respiratory diseases. After adjusting 192 
for major confounding factors, the primary finding of the current study was that, as with sarcopenia 193 
and obesity alone, sarcopenic obesity was associated with a greater risk of respiratory disease 194 
incidence. Furthermore, although sarcopenia and obesity showed a higher and lower risk for 195 
respiratory mortality, respectively, no associations between sarcopenic obesity and respiratory 196 
disease mortality were found.  197 
9 
 
Individuals with any form of obesity are more likely to increase symptoms of dyspnoea, asthma, 198 
sleep apnoea and reductions in FEV1. Those with obesity and respiratory disease have an increased 199 
risk for cardiovascular and metabolic diseases and, as a consequence, they have a higher reduction 200 
in the vital capacity, i.e., lower FEV1 (Table 1 and Supplementary Tables 1 and 2). Contrary to 201 
expectations, longitudinal studies have shown a decreased risk of mortality in obese patients with 202 
severe COPD in comparison to normal-weight people [18, 33]. These findings may be related to the 203 
phenomenon called “obesity paradox” [34]. Obesity may produce different effects depending on the 204 
degree of respiratory disease, having a protective effect in those with a severe condition but a worse 205 
prognosis in those with mild to moderate respiratory disease [16, 34]. However, the mechanism 206 
behind this association remains still unknown, and there are still gaps to elucidate and understand 207 
the paradox effect of obesity over respiratory disease. In our study, people with any form of obesity 208 
showed the lowest risk of respiratory disease mortality and case-fatality rate, having even a lower 209 
rate than people without sarcopenia nor obesity. In terms of sarcopenic obesity, obesity may have 210 
reduced the effect of sarcopenia over respiratory mortality, and this could be the explanation behind 211 
the decreasing in the magnitude of the association between sarcopenic obesity and respiratory 212 
mortality. In other words, the lack of a significant association could be due to the additive effect of 213 
obesity (possible protective factor) and sarcopenia (risk factor) in individuals with respiratory 214 
disease.  215 
Although many studies have been conducted between respiratory diseases, obesity and sarcopenia 216 
[14, 15], and between sarcopenic obesity and all-cause and CVD mortality [19-21], this is one of the 217 
first studies that examine the association between sarcopenic obesity and respiratory diseases 218 
incidence and mortality. In this context, futures studies are needed to support our findings and to 219 
determine the mechanism behind the association of sarcopenic obesity and respiratory mortality 220 
beyond the association of sarcopenia and obesity itself.  221 
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Finally, it is essential to emphasise that although there have been several attempts to define 222 
sarcopenic obesity and its cut-off points, the definition and diagnostic criteria remain insufficient 223 
and inadequate. Therefore, clarifying the cut-off points and definition beyond those for obesity and 224 
sarcopenia is critical to identify the real association between sarcopenic obesity and respiratory 225 
diseases. As a result, the European Society for Clinical Nutrition and Metabolism (ESPEN) and the 226 
European Association for the Study of the Obesity (EASO) did a call for more studies and more 227 
actions in this field [30].  228 
Strengths and limitations  229 
UK Biobank is not representative of the UK population in terms of lifestyle and disease prevalence 230 
[35]. Therefore, our estimates of absolute incidence and mortality should not be widespread. 231 
However, the use of UK Biobank provided the opportunity to test our research question in a large 232 
general population cohort as well as the opportunity to work with information collected using 233 
validated and standardised methods. In terms of sarcopenia, we did not use the new guideline 234 
proposed for the EWGSOP2 since its new cut-off points decrease the numbers of event and, 235 
therefore, the statistical power [36]. Dual-energy X-ray absorptiometry (DXA) is the most commonly 236 
used method for deriving muscle mass because it can provide a reproducible estimation of the 237 
appendicular skeletal muscle mass in a few minutes [37]. In UK Biobank, muscle mass was measured 238 
using BIA, but this method has been shown to correlate well with DXA (r=0.868, p<0.0001) and 239 
should provide a reasonable estimate within this large-scale study. Finally, the walking pace was self-240 
reported. While this is potentially a source of bias, it is more easily replicated in clinical practice. 241 
Furthermore, the walking pace has been identified as one of the strongest predictors of health 242 
outcomes, beyond many traditional risk factors (BMI, blood pressure, and smoking). 243 
In conclusion, all sarcopenic obesity definitions were positively associated with respiratory 244 
incidence. However, no significant associations between respiratory mortality and any definition of 245 
sarcopenic obesity were identified. Taking into account the lack of consensus related to cut-off 246 
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points and operational definition of sarcopenic obesity; futures studies are necessary to identify the 247 
possible mechanism behind this outcome as well as how to improve detection of sarcopenic obesity 248 
in the clinical practice. As a result, sarcopenic obesity remains a challenge and opportunity at the 249 
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Table 1. Cohort characteristics by sarcopenic obesity defined by Body Mass Index 359 
Normal Obesity Sarcopenia Sarcopenic 
obesity by BMI 
Socio-demographics 
Total n 44,138 70,607 20,300 3,509 
Sex (Female), n (%) 31,077 (70.4) 32,331 (45.8) 15,358 (75.7) 2,319  (66.1) 
















































































Height (meters), mean (SD) 1.68 (0.08) 1.70 (0.09) 1.64 (0.08) 1.65 (0.10) 
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Body weight (kg), mean (SD) 65.3 (8.0) 97.0 (13.5) 
 
61.0 (7.7) 87.1 (11.2) 
BMI, mean (SD) 23.2 (1.4) 33.6 (3.4) 22.5 (1.6) 32.0 (1.9) 




Normal weight (18.5-24.9 kg.m
-2
) 


























Waist Circumference (cm) 77.0 (7.3) 104.6 (10.5) 77.4 (7.7) 102.0 (9.9) 
Central Obesity, n (%) 0 60,558 (85.8) 0 3,182 (90.7) 
% Body fat, mean (SD) 24.5 (6.8) 36.6 (7.6) 29.4 (6.2) 
 
42.9 (6.0) 
% Body fat free (SD) 75.5 (6.8) 63.4 (7.6) 70.6 (6.2) 57.1(6.0) 













Physically active individuals n, (%) 11.0 (2.8) 8.8 (2.5) 9.2 (2.5) 7.4 (2.1) 
Grip Strength (kg), mean (SD) 31.8 (8.7) 35.1 (10.3) 19.3 (6.6) 22.1 (9.0) 
TV viewing (h.day
-1
), mean (SD) 2.1 (1.3) 3.0 (1.5) 2.8   (1.6) 3.8 (1.8) 




4.2 (1.9) 5.6 (2.4) 4.5   (2.0) 5.6 (2.4) 
Health status, n (%)     
FEV1 2.9 (0.7) 2.8 (0.8) 2.4 (0.6) 2.2 (0.6) 
Diabetes history 606 (1.4) 6,032 (8.6) 424 (2.1) 342 (9.8) 
CVDs history 5,427 (12.3) 29,515 (41.9) 4,293 (21.2) 1,770 (50.7) 
High blood pressure history 4,700 (10.7) 25,003 (35.5) 3,353 (16.6) 1,331 (38.1) 
BMI: body mass index; n: number; PA: physical activity; MET: metabolic-equivalent; TE: total energy; SD: standard 360 
deviation; CVD: cardiovascular disease. 361 
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Figure 1. Association between sarcopenic obesity, sarcopenia, obesity and respiratory disease 362 
incidence and mortality 363 
Data presented as adjusted hazard ratio (HR) and its 95% confidence interval (95%CI). Figure 1a shows the respiratory 364 
incidence and Figure b the respiratory mortality, both based on BMI. Normal people (without sarcopenia or obesity) were 365 
used as the reference group for the analysis. All analyses were conducted using a 2-years landmark analysis and by 366 
excluding participant with major diseases at baseline. Model was fully adjusted by age, sex, gross income, education 367 
attainment, hypertension, diabetes, depression, major illness, as well as CVD, cancer, smoking, sleep duration, physical 368 
activity, total discretionary sedentary time and dietary intake including alcohol, fruit and vegetable, oily fish, red meat and 369 
processed meat intake.  370 

